Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Non-Invasive Continuous Glucose Monitoring in Patients Without Diabetes: Use in Cardiovascular Prevention-A Systematic Review.
Sensors (Basel)
January 2025
Hochgebirgsklinik, Medicine Campus Davos, Herman-Burchard-Strasse 1, 7270 Davos, Switzerland.
Continuous glucose monitoring (CGM) might provide immediate feedback regarding lifestyle choices such as diet and physical activity (PA). The impact of dietary habits and physical activity can be demonstrated in real time by providing continuous data on glucose levels and enhancing patient engagement and adherence to lifestyle modifications. Originally developed for diabetic patients, its use has recently been extended to a non-diabetic population to improve cardiovascular health.
View Article and Find Full Text PDFHealth and Liver Diagnostic Markers Influencing Glycemia in Subjects with Prediabetes: Preview Study.
Diagnostics (Basel)
December 2024
Centre for Nutrition Research, Department of Nutrition, Food Science, Physiology and Toxicology, University of Navarra, 31009 Pamplona, Spain.
Introduction: Glucose homeostasis may be dependent on liver conditions and influence health-related markers and quality of life (QoL) objective measurements. This study aimed to analyze the interactions of glycemia with liver and health status in a prediabetic population.
Subjects And Methods: This study included 2220 overweight/obese prediabetics from the multinational PREVIEW project.
Effect of digital health applications with or without gamification on physical activity and cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials.
EClinicalMedicine
October 2024
Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Center, St. Michael's Hospital, Unity Health Toronto, Toronto, ON M5B 1W8, Canada.
Background: Use of health applications (apps) to support healthy lifestyles has intensified. Different app features may support effectiveness, including gamification defined as the use of game elements in a non-game situation. Whether health apps with gamification can impact behaviour change and cardiometabolic risk factors remains unknown.
View Article and Find Full Text PDFAdequate sleep duration accentuates the effect of glucagon-like peptide-1 receptor variant on HbA1c: A gene-environment interaction study.
Diabetes Res Clin Pract
December 2024
Department of Big Data in Health Science, Zhejiang University School of Public Health and Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; The Key Laboratory of Intelligent Preventive Medicine of Zhejiang Province, Hangzhou, China; Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Electronic address:
Background: Both glucagon-like peptide-1 receptor (GLP1R) agonists and lifestyle modifications are widely adopted in managing glycemia. However, the joint effects of GLP1R agonists with lifestyle on glycemic traits have not been evaluated.
Methods: This gene-environment study tested the interaction between GLP1R-rs10305492 variant, consistent with the effect of GLP1R agonist therapies, and four lifestyle factors (diet, physical activity, sleep duration, and chronotype) for glucose and glycated hemoglobin (HbA1c) levels among 263,846 UK Biobank participants.
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).
Obesity (Silver Spring)
January 2025
Section of Obesity Medicine and Center for Digestive Health, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Objective: The objective of this study was to describe the rationale and design of two multinational phase 3 clinical trials of survodutide, an investigational glucagon and glucagon-like peptide-1 receptor dual agonist for the treatment of obesity with or without type 2 diabetes (T2D; SYNCHRONIZE-1 and -2).
Methods: In these ongoing double-blind trials, participants were randomized to once-weekly subcutaneous injections of survodutide or placebo added to lifestyle modification. Survodutide doses are uptitrated to 3.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!